ArticleAnnals of hematology2025

A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta

Aziz Eghbali et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.